Aktis Oncology, Inc. (AKTS) vs MeiraGTx Holdings plc (MGTX)

A side-by-side comparison of Aktis Oncology, Inc. and MeiraGTx Holdings plc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Aktis Oncology, Inc. logo
AKTS
Aktis Oncology, Inc.
$986M
$18.47HealthcareDelayed quote: Oct 6, 2026, 10:50 AM EDT
MeiraGTx Holdings plc logo
MGTX
MeiraGTx Holdings plc
$985M
$10.64HealthcareDelayed quote: Oct 6, 2026, 10:50 AM EDT

Total return — AKTS vs MGTX

growth of $100 · dividends reinvested · last 1y
AKTS -17.3% (-17.3%/yr)MGTX +41.3% (+41.3%/yr)MGTX compounded faster over this window
100150Start $100$83$141
AKTS MGTX

AKTS vs MGTX: by the numbers

  • •AKTS is the larger company ($986M vs $985M market cap).
  • •MGTX is profitable (19.87% net margin) while AKTS runs a net loss (-727.04%).

Metrics side by side

Valuation

MetricAKTSMGTX
P/E ratioN/A14.99
Forward P/EN/A35.47
P/S ratio98.042.48
P/B ratio2.034.57
EV / EBITDAN/A4.86

Profitability

MetricAKTSMGTX
Gross margin100.00%97.19%
Operating margin-1149.52%-130.20%
Net margin-727.04%19.87%
ROE-15.09%36.64%
ROIC-16.54%52.81%

Growth (annualized)

MetricAKTSMGTX
Revenue CAGR (5Y)N/A84.52%
Total return CAGR (5Y)N/A-3.10%

Some values include inputs from SEC filing.

Frequently asked

Is AKTS or MGTX more profitable?
MGTX runs the higher net margin — AKTS at -727.04% versus MGTX at 19.87%.

Go deeper

Full AKTS analysisFull MGTX analysisInteractive comparison tool

Dig into the metrics

MeiraGTx P/E ratioAktis Oncology ROEMeiraGTx ROEAktis Oncology operating marginMeiraGTx operating marginAktis Oncology revenue growthMeiraGTx revenue growthAktis Oncology free cash flowMeiraGTx free cash flow

Aktis Oncology & MeiraGTx appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.